1240518-54-0

Basic information

• Product Name: 3-AMino-1H-indazole-4-carbonitrile
• Synonyms: 3-AMino-1H-indazole-4-carbonitrile
• CAS NO: 1240518-54-0
• Molecular Formula: C8H6N4
• Molecular Weight: 158.16004
• Mol File: 1240518-54-0.mol

Chemical Properties

• Boiling Point: 472.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.50±0.40(Predicted)
• CAS DataBase Reference: 3-AMino-1H-indazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMino-1H-indazole-4-carbonitrile(1240518-54-0)
• EPA Substance Registry System: 3-AMino-1H-indazole-4-carbonitrile(1240518-54-0)

Safety Data

• Hazardous Substances Data: 1240518-54-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Amino-1H-indazole-4-carbonitrile is used as a key building block for the synthesis of various pharmaceuticals and agrochemicals. Its presence in these compounds is attributed to its ability to enhance their biological activity and therapeutic potential.
Used in Antifungal and Antitumor Applications:
3-Amino-1H-indazole-4-carbonitrile is utilized as an antifungal and antitumor agent due to its potential to combat fungal infections and inhibit tumor growth. Its effectiveness in these applications is a result of its unique chemical structure and reactivity.
Used in Organic Synthesis:
3-Amino-1H-indazole-4-carbonitrile is employed as a valuable tool in organic synthesis, where its diverse reactivity allows for the creation of a wide range of chemical products with various applications.
Used in Textile Industry as a Dye Intermediate:
In the textile industry, 3-Amino-1H-indazole-4-carbonitrile is used as a dye intermediate, contributing to the development of new dyes with improved properties and performance.
Overall, 3-Amino-1H-indazole-4-carbonitrile's wide range of applications and its role as a key component in the development of important chemical products highlight its significance in various industries.

Upstream product

• 65610-13-1 3-fluoro-1,2-benzenedicarbonitrile 

Downstream Products

• 1240517-77-4 N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(hydroxymethyl)-1H-indazol-1-yl]methyl}phenyl)methyl]acetamide 
• 1240518-61-9 N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(difluoromethyl)-1H-indazol-3-yl]-5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-2-thiophenesulfonamide 
• 1240518-60-8 1,1-dimethylethyl [(3-{[3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-(difluoromethyl)-1H-indazol-1-yl]methyl}phenyl)methyl]carbamate 
• 1240518-63-1 N-[1-{[3-(aminomethyl)phenyl]methyl}-4-(hydroxymethyl)-1H-indazol-3-yl]-5-chloro-N-[(5-chloro-2-thienyl)sulfonyl]-2-thiophenesulfonamide 
• 1240518-62-0 1,1-dimethylethyl [(3-{[3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-(hydroxymethyl)-1H-indazol-1-yl]methyl}phenyl)methyl]carbamate 
• 1240518-59-5 1,1-dimethylethyl ({3-[(3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-formyl-1H-indazol-1-yl)methyl]phenyl}methyl)carbamate 
• 1240518-64-2 1,1-dimethylethyl ({3-[(3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-cyano-1H-indazol-1-yl)methyl]phenyl}methyl)carbamate 
• 1240518-58-4 1,1-dimethylethyl ({3-[(3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-cyano-1Hindazol-1-yl)methyl]phenyl}methyl)carbamate 
• 1240518-65-3 N-({3-[(3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-cyano-1H-indazol-1-yl)methyl]phenyl}methyl)acetamide 
• 1240518-84-6 C₂₀H₁₆ClN₅O₂S₂ 
• 1240518-81-3 N-[(3-{[3-{bis[(5-chloro-2-thienyl)sulfonyl]amino}-4-(difluoromethyl)-1H-indazol-1-yl]methyl}phenyl)methyl]acetamide 
• 1240517-76-3 N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(difluoromethyl)-1H-indazol-1-yl]methyl}phenyl)methyl]acetamide 
• 1240517-79-6 N-[(3-{[3-{[(5-chloro-2-thienyl)sulfonyl]amino}-4-(1-hydroxy-1-methylethyl)-1H-indazol-1-yl]methyl}phenyl)methyl]acetamide 
• 1240517-78-5 N-[(3-{[3-{[(5-Chloro-2-thienyl)sulfonyl]amino}-4-(1-hydroxyethyl)-1H-indazol-1-yl]methyl}phenyl)methyl]acetamide 

Relevant articles and documents

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists

A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists. Methoxy- or hydroxyl- containing groups were the more potent indazole C4 substituents. Only small groups were tolerated at C5, C6, or C7, with the C6 analogues being preferred. The most potent N3-substituent was 5-chlorothiophene-2-sulfonamide. N1 meta-substituted benzyl groups possessing an α-amino-3-[(methylamino)acyl]- group were the most potent N1-substituents. Strongly basic amino groups had low oral absorption in vivo. Less basic analogues, such as morpholines, had good oral absorption; however, they also had high clearance. The most potent compound with high absorption in two species was analogue 6 (GSK2239633A), which was selected for further development. Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II. X-ray diffraction studies on two indazole sulfonamide fragments suggested the presence of an important intramolecular interaction in the active conformation.

NOVEL COMPOUNDS

Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.